Datasheet for ABIN2715279

BIRC7 Protein (Transcript Variant 2) (Myc-DYKDDDDK Tag)

Go to Product page

1 Image

Overview

Quantity:	20 µg
Target:	BIRC7
Protein Characteristics:	Transcript Variant 2
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Purification tag / Conjugate:	This BIRC7 protein is labelled with Myc-DYKDDDDK Tag.
Application:	Antibody Production (AbP), Standard (STD)

Product Details

Characteristics:	• Recombinant human BIRC7 / LIVIN (transcript variant 2) protein expressed in HEK293 cells. • Produced with end-sequenced ORF clone
Purity:	> 80 % as determined by SDS-PAGE and Coomassie blue staining

Target Details

Target:	BIRC7
Alternative Name:	Birc7,livin (BIRC7 Products)
Background:	This gene encodes a member of the inhibitor of apoptosis protein (IAP) family, and contains a single copy of a baculovirus IAP repeat (BIR) as well as a RING-type zinc finger domain. The BIR domain is essential for inhibitory activity and interacts with caspases, while the RING finger domain sometimes enhances antiapoptotic activity but does not inhibit apoptosis alone.

Copyright antibodies-online. All rights reserved.

Target Details

	Elevated levels of the encoded protein may be associated with cancer progression and play a role in chemotherapy sensitivity. Alternative splicing results in multiple transcript variants
Molecular Weight:	30.7 kDa
NCBI Accession:	NP_071444

Application Details

Application Notes:	Recombinant human proteins can be used for: Native antigens for optimized antibody production Positive controls in ELISA and other antibody assays
Comment:	The tag is located at the C-terminal.
Restrictions:	For Research Use only

Handling

Concentration:	50 µg/mL
Buffer:	25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
Storage:	-80 °C
Storage Comment:	Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Images



Western Blotting

Image 1. Validation with Western Blot

Copyright antibodies-online. All rights reserved.